• ImmuneOnco Biopharmaceuticals shareholders will vote at an extraordinary general meeting on appointing ZHONGHUI ANDA as auditor for 2026, replacing Deloitte.
• The appointment would take effect upon shareholder approval and run until the next annual general meeting.
• Deloitte resigned over an audit-fee disagreement arising from increased audit work related to a subsidiary’s capital increase.
• ZHONGHUI proposed an audit fee of RMB 1.6 million, compared with Deloitte’s RMB 2.7 million.
• The board and audit committee consider the appointment in shareholders’ best interests, with no expected reduction in audit quality.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261028-12386807), on October 28, 2026, and is solely responsible for the information contained therein.